Möricke, Esmé http://orcid.org/0000-0001-6011-4913
Greven, Corina U.
Visser, Janne C.
Oosterling, Iris J.
Buitelaar, Jan K.
Rommelse, Nanda N. J. http://orcid.org/0000-0002-1711-0359
Funding for this research was provided by:
ZonMW Research Program Chronic Diseases (CZ-TT 940-38-045)
Innovative Medicines Initiative Joint Undertaking (EU-AIMS 115300)
European Union's Seventh Framework Program (FP7/2007-2013)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Horizon 2020 Marie Sklodowska-Curie ETN Grant (BRAINVIEW 642996)
Article History
Received: 3 June 2018
Accepted: 30 December 2018
First Online: 29 March 2019
Compliance with ethical standards
:
: In the past 3 years, Buitelaar has been a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Schering Plough, UCB, Shire, Novartis and Servier. He is not an employee or a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. The other authors declare that they have no conflict of interest.
: All procedures performed in this study involving human participants were approved by the institutional research committee. The study has been performed in accordance with the international ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual participants included in the study.